Last updated on 03 July 2025
In line with the Ministry of Health’s efforts to enhance preventive care, a new National Familial Hypercholesterolaemia (FH) Genetic Testing Programme has been introduced to support early identification of patients with FH, with effect from 30 June 2025.
FH is an inherited genetic condition causing impaired LDL-cholesterol (LDL-C) metabolism and predisposes to early onset atherosclerotic cardiovascular disease (ASCVD). Early detection of FH through LDL-C screening, gene testing, and cascade screening is crucial for managing FH and reducing the lifetime risk of ASCVD and death.